Arterial Embolization Hyperthermia Using As$_2$O$_3$ Nanoparticles in VX$_2$ Carcinoma–Induced Liver Tumors

Hui Yu$^1$, Guang-Yu Zhu$^1$, Rui-Zhi Xu$^2$, Huan-Zhong Niu$^1$, Qin Lu$^1$, Guo-Zhao Li$^1$, Zi-Yu Wang$^3$, Dong-Sheng Zhang$^3$, Ning Gu$^2$, Gao-Jun Teng$^1$

$^1$Jiangsu Key Laboratory of Molecular Imaging and Functional Imaging, Department of Radiology, Zhong-Da Hospital, Medical School of Southeast University, Nanjing, China, $^2$Jiangsu Laboratory for Biomaterials and Devices, State Key Laboratory of BioElectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China, $^3$Department of Pathology and Pathophysiology, Medical School of Southeast University, Nanjing, China

Abstract

**Background:** Combination therapy for arterial embolization hyperthermia (AEH) with arsenic trioxide (As$_2$O$_3$) nanoparticles (ATONs) is a novel treatment for solid malignancies. This study was performed to evaluate the feasibility and therapeutic effect of AEH with As$_2$O$_3$ nanoparticles in a rabbit liver cancer model. The protocol was approved by our institutional animal use committee.

**Methodology/Principal Findings:** In total, 60 VX$_2$ liver-tumor-bearing rabbits were randomly assigned to five groups (n = 12/group) and received AEH with ATONs (Group 1), hepatic arterial embolization with ATONs (Group 2), lipiodol (Group 3), or saline (Group 4), on day 14 after tumor implantation. Twelve rabbits that received AEH with ATONs were prepared for temperature measurements, and were defined as Group 5. Computed tomography was used to measure the tumours’ longest dimension, and evaluation was performed according to the Response Evaluation Criteria in Solid Tumors. Hepatic toxicity, tumor necrosis rate, vascular endothelial growth factor level, and microvessel density were determined. Survival rates were measured using the Kaplan-Meier method. The therapeutic temperature (42.5°C) was obtained in Group 5. Hepatotoxicity reactions occurred but were transient in all groups. Tumor growth was delayed and survival was prolonged in Group 1 (treated with AEH and ATONs). Plasma and tumor vascular endothelial growth factor and microvessel density were significantly inhibited in Group 1, while tumor necrosis rates were markedly enhanced compared with those in the control groups.

**Conclusions:** ATON-based AEH is a safe and effective treatment that can be targeted at liver tumors using the dual effects of hyperthermia and chemotherapy. This therapy can delay tumor growth and noticeably inhibit tumor angiogenesis.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common fatal malignant tumors worldwide [1]. Surgical removal remains the gold standard for liver cancer. However, the majority of tumors are inoperable because diagnosis is seldom established in the early stages [2,3]. Hyperthermia, a therapeutic procedure that raises the temperature of a tumor, has attracted increasing attention as a promising approach to cancer therapy [4–6]. The rationale for the use of hyperthermia is that sustained temperatures above 42.5°C directly kill living cells. Compared with chemotherapy and radiotherapy, hyperthermia has fewer side effects.

Transcatheter arterial chemoembolization (TACE) has been established as a nonsurgical treatment for HCC, and many studies have established its safety and efficacy, with long-term survival rates comparable to those seen following surgical resection [2,7]. The rationale for this procedure is that the normal liver parenchyma receives two-thirds of its blood supply from the portal vein system, whereas tumors in the liver derive virtually all of their blood supply from the hepatic arterial system. Thus, for hepatic tumors, substances injected into the hepatic arterial system will be preferentially delivered to the liver tumor. This same principle can be used in arterial embolization hyperthermia (AEH), which has been used as a localized modality of hyperthermia for many years and has shown promise in recent experimental animal studies. In AEH, tumor tissue is heated specifically, sparing surrounding normal hepatic tissue [8–10].

Arsenic trioxide (As$_2$O$_3$) has been successfully used to treat patients with acute promyelocytic leukemia [11]. Recent studies have shown that As$_2$O$_3$ has antitumor activity towards many solid tumors, including hepatomas [12–14]. Its mechanisms of action include induction of apoptosis of various cancer cell lines [15], inhibition of tumor growth [16], and angiogenesis [17].

The purpose of the present study was to evaluate the safety and the anticancer effects of the use of As$_2$O$_3$ nanoparticles combined with AEH in established transplanted rabbit VX$_2$ hepatic tumors.
Results

Technical Success

The TAE and CT procedures were successfully performed in all animals with the exception of two rabbits. One rabbit in Group 1 died during general anesthetic induction within the scheduled CT follow-up on day 3 after TAE, and another rabbit in Group 4 died 6 h after a sham procedure on Day 1. Both animals were excluded from analyses.

Morphology of ATONs

Transmission electron microscopy (Fig. 1) showed ATONs to be approximately spherical, with diameters of about 40 nm. Immediately after intra-arterial injection (Fig. 2A, B), lipiodol or ATONs suspended in lipiodol were concentrated in the margin of the tumor, mainly in vascular channels. Even 2 weeks after intra-arterial injection, retention of lipiodol or ATONs persisted, suggesting that clearance of the agent was much faster from normal liver than from tumors (Fig. 3A–D).

Heating Curve

Intratumor and rim temperatures (Figs. 4A–C) rapidly increased to 42.5°C within 5 min, and were then maintained above 42.5°C for 30 min by carefully manipulating the magnetic field intensity. All nontumor heating levels were safely below 41°C during treatment. The heating rate was much greater in the center and periphery of the tumor than in normal hepatic parenchyma (NHP), and was highest at the rim of the tumor.

Biochemical Tests

Liver function test results (Fig. 5A, B) showed that AST and ALT levels tended to increase transiently 1 day after intra-arterial embolization and last for several days following the infusion, regardless of which agent was administered. Plasma TBil (Fig. 5C), BUN (Fig. 5D) and Cr (Fig. 5E) levels did not change appreciably in any group. Elevated AST and ALT levels were transient and significant (P < 0.05) 1 day after intra-arterial embolization and hyperthermia, but decreased to levels close to normal by 14 days after intra-arterial embolization. There were no significant differences in biochemical values among the four groups at days 14 or 21 (P > 0.05).

Histopathological Findings

Treated tumors (Figures 6A to C) were considerably smaller than untreated tumors (Fig. 6D). It was evident that the ATONs concentrated primarily around the periphery of tumors and were confined within blood vessels, while only a few penetrated the central core region, which was poorly vascularized (Fig. 7A). Massive necrosis and a thick fibrocollagenous capsule around the tumor, but no viable tumor cells, were seen in the specimen of AEH plus ATONs obtained on day 7. Adjacent liver parenchyma appeared normal (Fig. 7B). Tumors in the ATON group (Fig. 7D) had histological findings similar to those in the AEH plus ATON group, except that completely necrotic portions were more prominent in the AEH plus ATONs group. In the iodized-oil group, partial necrosis occurred only in the central regions of tumors (Fig. 7G). In contrast, control tumors showed clusters of viable tumor cells with lighter regions of necrosis and cellular debris (Fig. 7H). No ATONs appeared in the lungs or kidneys of any specimens. Macrophages were associated with occasional ATONs aggregated in the spleen 14 days after ATON arterial embolization (Fig. 7I).

Quantitative analysis of microvessels. Quantitative MVD data from each group are presented in Table 2. A significant reduction in MVD was noted in Group 1, which was treated with ATONs plus hyperthermia (Figs. 8A–D).

VEGF expression. In Group 1, plasma VEGF levels were elevated at day 3 after ATON plus hyperthermia treatment, followed by a significant decrease through days 7, 10, 14, and 21 (Table 3). Group 1 also had significantly lower VEGF levels in tumors compared with Group 2 (P = 0.003; Table 4). The VEGF-positive rate was significantly lower in Group 1 than in Group 4 (P = 0.0027) or Group 3 (P < 0.001). The difference between Groups 1 and 2 was not statistically significant (Table 4, Fig. 8E–H).

Tumor necrosis. The mean tumor necrosis rates of the tumors in each group are given in Table 2. The ATON plus hyperthermia group (Group 1) showed the highest tumor necrosis rates (P < 0.001).

Survival

All rabbit deaths during the course of the study were caused by hepatic and/or respiratory failure secondary to extensive tumor burden. All of these events occurred within 57 days, reflecting the aggressive nature of this tumor model.

Even though no rabbits were completely cured, animals in the AEH plus ATON group survived significantly longer than did the controls (Kaplan-Meier method with log-rank test, P < 0.001; Fig. 9).

Discussion

Although currently available TACE may result in a modest improvement in HCC patient survival, a radiological complete response is achieved in only 35% of patients according to EASL...
criteria [19]. The overall prognosis of these patients remains poor [20,21]. However, eligible patients have already benefited from available hyperthermia technologies [22,23] including radiofrequency, which heats not only the tumor but also the surrounding healthy tissue. Another limit of radiofrequency is the cooling effect of the intact blood supply [8], which results in nonuniform heating of the target area. Thus, development of more effective therapies is urgently needed.

AEH is based on using the arterial supply of a tumor to provide a pathway for selective embolization of the tumor by using magnetic particles, followed by exposure to an alternating magnetic field to generate heating of the embolized particles by hysteresis or Neél relaxation. Briefly, Neél loss is caused by the relaxation of magnetization vector rotation of single-domain magnetic particles in an applied AC field, while hysteresis loss is heat loss caused by the magnetic properties of the armature.

As$_2$O$_3$ is currently being tested against various malignancies, including HCC [11–14,24,25]. However, its clinical application is limited by its narrow therapeutic window. Alternatively, ATONs deliver local treatment and potentially achieve therapeutic efficacy by improving tumor/normal tissue uptake ratios; furthermore, they avoid toxicity by reducing uptake of ATONs by nontarget organs [26]. Both the antivascular effects and direct cellular thermosensitization of As$_2$O$_3$ contributed to the increase in heat-induced tumor growth delay observed in these studies [24]. As$_2$O$_3$ reduces the blood flow in vivo and prolongs the dwell time of the drug within the tumor, and preferential uptake of iodized oil would be expected to increase the amount of drug directed at the tumor [27]. Thus, we believe that ATONs combined with AEH could exert a synergistic antitumor effect via two properties: chemotherapy of As$_2$O$_3$ and thermotherapy of magnetic Fe$_3$O$_4$ nanoparticles.

Our hyperthermia system consists primarily of a ferrite-core applicator with an aperture with a 350-mm vertical distance, 300-mm length, and 200-mm width (large enough to accommodate a rabbit or even larger animals). The device is operated at a frequency of 80 kHz, and the field strength can be adjusted from 5 to 10 kA/m. Our hyperthermia system can generate high temperatures. To determine the possibility of using either AMF or lipiodol in heating, a preliminary experiment was performed with another group of animals using saline or lipiodol. A FISO probe was introduced into the tumor, showing that the AMF was activated; we had to exclude the possibility that the magnetic field itself was contributing to any change in temperature or tumor growth (data not shown).

Figure 2. Representative rabbit hepatic angiographic images. Figure 2A Selective placement of 3F microcatheter (white arrow) and injection of ATONs suspended in lipiodol in the proper left hepatic artery revealed ill-defined hypervascularity tumor staining in the left lobe. Figure 2B Postembolization images show complete stasis of blood flow and demonstrate dense staining of the tumor bed, suggesting successful delivery and excellent distribution of the magnetic nanoparticle fluid mixture in the tumor. doi:10.1371/journal.pone.0017926.g002

Figure 3. Serial CT imaging findings after TAE. Figure 3A CT scan obtained immediately after TAE. ATONs have accumulated primarily in the tumor (black arrow), whereas ATON retention in the NHP region (white arrow) is minimal. Figure 3B CT scan obtained 3 days after TAE shows ATONs retained in the tumor (black arrow). The number of ATONs within the NHP region is decreasing. Figure 3C Seven days after TAE (4 days after AEH), ATONs are selectively retained in the tumor (black arrow), whereas they are barely visible within the NHP region. Figure 3D Fourteen days after TAE (11 days after AEH), ATONs are still observed in the tumor region, and have especially accumulated in the peripheral area. doi:10.1371/journal.pone.0017926.g003
Over the last decade, several studies [9, 28–30] have investigated the potential of various magnetic nanoparticles, including maghemite cationic liposomes, $\gamma$-Fe$_2$O$_3$, and Fe$_3$O$_4$ in AEH. Our study is the first report on the therapeutic effects of ATONs in an animal HCC tumor model. In a previous study, we evaluated the different heating abilities of $\gamma$-Fe$_2$O$_3$ nanoparticles and ATONs. The magnetic properties of the nanoparticles were shown in a hysteresis loop (Fig. S1), which indicated that $\gamma$-Fe$_2$O$_3$ had a higher specific absorption rate (21.4 $\pm$ 10$^3$ W/kg Fe) than ATONs (18.2 $\pm$ 10$^3$ W/kg Fe) under an alternating current magnetic field of 10 kA/m and 80 kHz. However, both nanoparticles achieved therapeutic temperatures in the in vivo experiment.

Our self-prepared ATONs combined with hyperthermia had a significant therapeutic effect on VX2 liver cancers. Tumor growth was delayed, angiogenesis was inhibited, survival time was prolonged, and side effects were endurable. Our promising results are consistent with and extend a previous study [31], which showed that a combination of nanosized As$_2$O$_3$/$\gamma$-Fe$_2$O$_3$ complexes has a substantially greater inhibitory effect than either agent alone. The findings from our present study may be explained by synergy between ATON embolization and hyperthermia. ATON embolization is able to block the flow of blood to a tumor, reduce tumor perfusion, and decrease heat dissipation [24, 25], which further enhances the hyperthermic therapeutic effect, and inhibit angiogenesis [17, 32]. The antiangiogenic effect of ATON embolization plus hyperthermia was demonstrated by quantitative MVD analysis and ELISA analysis of decreased VEGF expression in tumors and plasma.

Our results indicate that AEH using ATONs can specifically heat tumor tissue without damaging adjacent healthy tissue. It has been demonstrated that tissue iron concentrations are linearly related to heating rates [9, 27]. The antiangiogenic effect of ATON embolization plus hyperthermia was demonstrated by quantitative MVD analysis and ELISA analysis of decreased VEGF expression in tumors and plasma.

Figure 4. Temperature profiles during AEH treatment. Figure 4A Typical heating curve for the temperature of the tumor core, rim, normal liver tissue, and rectum of Subject 1 in Group 5, from baseline to temperature during AEH treatment. Figure 4B Typical mean heating curve for the temperature of each subject in Group 5 during AEH treatment. Intratumor and rim temperatures increase rapidly to 42.5 °C within 5 min and are then maintained above 42.5 °C for 30 min, while the temperature inside NHP and the rectum remain below 40 °C. Figure 4C Intratumor and rim delta temperature changes show the specific heating of the tumor during treatment.

Prepared by: Holger M. Schmidt, MD
Arterial Embolization Hyperthermia on Hepatoma
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17926
in better heat conduction and poorer cooling mechanisms due to poorer blood perfusion (as a result of the absence of an ordered, high-flow, portal venous system) within the necrotic regions of tumors. Poorer blood flow through the center of tumors may favor the flow of heat into the tumor core from the hotter rim. Previous results [33] support this assertion.

The distribution and clearance of ATONs are important issues for the potential clinical application of ATONs. We injected ATONs into the hepatic artery; most ATONs went to targeted liver tumors. ATONs deposited in either normal liver or tumor tissue were still clearly visible on CT images or pathology slices several weeks after ATON injection. The long deposition time of ATONs in NHP may lead to unexpectedly high temperatures in healthy tissue during treatment. However, clearance of ATONs was much faster from tumors than from NHP. Therefore, we implemented hyperthermia 3 days after TAE. This reduced the potential threat of liver dysfunction in rabbits treated with TAE plus hyperthermia. However, in a clinical setting, superselective catheterization of the tumor-feeding artery could be performed before arterial embolization and hyperthermia, which would spare as much normal liver tissue as possible and reduce ATON deposition, thus preventing this potential complication. On the other hand, sparse distribution of ATONs in NHP cannot be avoided, but the large portal blood flow would cool these point sources of heat and thus prevent thermal damage to NHP. Our results demonstrate that the temperature of NHP remained at safe levels (below 41 °C) during treatment. Furthermore, our results are consistent with those of Moroz et al. [9], who showed that the lack of a raised temperature in the rectum indicates that no significant body core heating has occurred. This indicates that either no ATONs passed through the hepatic circulation into the systemic circulation or no significant nonhepatic tissue heating occurred.

Histological analysis of lung and kidney tissues failed to show evidence that ATONs passed through the liver and lodged within the lungs or kidneys. The finding of ATON aggregates within macrophages in the liver and spleen suggests that ATONs may be eliminated from the liver and spleen over time. Examination of splenic tissue (day 14) revealed some macrophages in association with ATONs, while splenic tissue at days 1, 3, and 10 failed to show them, presumably indicating that ATONs were not removed by macrophages before day 14 after TAE. This may be an advantage, because this time interval allows for a sufficient number

### Table 1. Tumor Response by RECIST criteria.

| Tumor Response | Complete Response (%) | Partial Response (%) | Stable Disease (%) | Progressive Disease (%) |
|----------------|-----------------------|----------------------|--------------------|-------------------------|
| Group 1 (n = 7)| 0                     | 7 (100)             | 0                  | 0                       |
| Group 2 (n = 8)| 0                     | 4 (50)              | 4 (50)             | 0                       |
| Group 3 (n = 7)| 0                     | 2 (28.5)            | 2 (28.5)           | 3 (43)                  |
| Group 4 (n = 8)| 0                     | 0                   | 0                  | 8 (100)                 |

doi:10.1371/journal.pone.0017926.t001
Figure 6. Gross pathologic specimens of response to different treatment. Figure 6A and B Gross pathologic specimens of ATON-induced necrosis in VX2 liver tumors treated with ATON embolization plus hyperthermia (A) and with ATON embolization alone (B). C: Lipiodol embolization resulted in significantly (P < 0.05) larger tumors than those of groups 1 or 2 at day 14. D: Gross pathologic specimens of a tumor from an NS control rabbit (Group 4), showing a solitary mass (T) and intrahepatic metastasis (M) at the time of death.
doi:10.1371/journal.pone.0017926.g006

Figure 7. Representative histopathological (H&E) findings. Figure 7 A–I: A: Original magnification: H&E, 100×. Section of a VX2 liver tumor treated with AEH mediated by ATONs (A) at the periphery, which was surrounded by NHP (H). A necrotic central core (N) is surrounded by an area of debris, inflammatory reaction, and fibrosis. B: Original magnification: H&E, 100×. Section through NHP 7 days after arterially embolized ATONs. The liver architecture is preserved. C: For each H&E histological image, both an outer tumor border (red line) and inner regions of necrosis (green line) were manually circumscribed to permit reference-standard histopathology-based necrosis-rate measurements. Original magnification: H&E, 25×. D: Original magnification: H&E, 100×. Microscopic image in Subject 4 from Group 2 treated with ATON embolization, showing ATONs deposited within the vascular system. Three days after embolization, an area of necrosis together with inflammatory cell infiltration and extensive fibrosis surrounding the necrotic area were evident. The area of necrosis was not as extensive as in Group 1. E: Original magnification: H&E, 100×. Pathological specimen from a rabbit in the hyperthermia group shows massive necrosis of the tumor and aggregates of ATONs that have embolized within the vascular system of the tumor. The VX2-implanted region in the liver has been replaced by scar tissue. Histological changes include hemorrhage, chronic inflammation, and necrosis. No viable tumor cells are evident in either the rim or center of the tumor. F: Original magnification: H&E, 200×. ATON aggregates confined within a blood vessel, surrounded by necrotic tumor cells 14 days after ATON arterial embolization. The tumor cells in the treated animal appear shrunken, and their nuclei are pyknotic. G: Original magnification: H&E, 100×. H&E-stained micrograph of a lipiodol-treated tumor at day 7 showing the presence of damaged tumor cells; note the intermixed areas of clearly viable tumor (V), indicating potential spread of the tumor beyond its circumscribed boundary. H: Original magnification: H&E, 100×. H&E-stained section of tumor from a control rabbit (Group 4) shows areas of viable tumor (V). I: Original magnification: H&E, 200×. Macrophages associated with ATON aggregates (black arrow) in the spleen 14 days after ATON arterial embolization.
doi:10.1371/journal.pone.0017926.g007
of repeat heat treatments which can enhance hyperthermic effect. We believe that it represents an important prerequisite for the clinical application of this technique in liver cancer.

AEH has not yet been tested in humans, and the clinically relevant dosage remains largely unknown. The net \( \gamma \)-Fe\(_2\)O\(_3\) dose (21.2 mg/kg body weight) applied in our regional procedure was similar to those of previous preclinical hyperthermia studies, which showed effective inhibition of tumor growth by hepatic arterial administration of nanoparticles at doses of 25–100 mg in each rabbit with hepatic orthotopic VX\(_2\) carcinoma [8,9,27]. On the other hand, the net As\(_2\)O\(_3\) dose (2.8 mg/kg body weight) applied in our study was clearly within the dose range of previous studies, which used As\(_2\)O\(_3\) to treat experimental solid tumors after single or multiple doses of 1–10 mg/kg [16,24,25,34–40]. However, such doses are considerably higher than the daily dose of 0.16–0.24 mg/kg given for several weeks in a recent phase II clinical trial, which was not active against advanced HCC [41].

### Table 2. MVD and Mean Tumor Necrosis Ratios in Different Groups.

| Group | Mean necrotic area ratios (% (mean±SD)) | MVD (mean±SD) |
|-------|----------------------------------------|---------------|
| 1(n=4) | 92.08±2.62\(^{ab}\)                  | 17.95±5.44\(^{ab}\) |
| 2(n=4) | 84.00±4.75\(^{a}\)                  | 32.85±7.53\(^{ab}\) |
| 3(n=4) | 59.75±10.59\(^{f}\)                  | 76.30±19.16    |
| 4(n=4) | 44.63±10.96                         | 63.05±11.20    |

Mann-Whitney U Test:

\*G1 vs. G2 \(p=0.000\);
\*G1 vs. G3 \(p=0.000\);
\*G1 vs. G4 \(p=0.000\);
\*G2 vs. G3 \(p=0.000\);
\*G2 vs. G4 \(p=0.000\);
\*G3 vs. G4 \(p=0.000\);
\*G1 vs. G2 \(p=0.000\);
\*G1 vs. G3 \(p=0.000\);
\*G1 vs. G4 \(p=0.000\);
\*G2 vs. G3 \(p=0.000\);
\*G2 vs. G4 \(p=0.000\).

doi:10.1371/journal.pone.0017926.t002

Conclusions

AEH with ATONs inhibited tumor growth in most treated animals with temporal hepatic dysfunction, and significantly improved survival in the intrahepatic VX\(_2\) tumors in our study. The therapeutic effect of AEH may be further enhanced when it is combined with ATONs, the antitumor effects of which are partly due to inhibition of tumor angiogenesis but also correlated with altered VEGF expression in the tumor and plasma. Further studies aimed at elucidating the optimal dose and mechanism in animals, and ultimately clinical trials, are required.

![Figure 8. Immunohistochemical staining for CD31 and VEGF.](image-url)

Legend: Representative immunohistochemical staining with CD31 and VEGF monoclonal antibodies in VX\(_2\) liver tumors in each group. Microvessels are identified by dark brown (original magnification, 200 \times\). A marked reduction in MVD is observed in the ATON plus hyperthermia group (A) and ATON embolization alone group (B). Abundant microvessels are evident in both the lipiodol TAE group (C) and NS control group (D). Positive VEGFs are recognizable as intensely stained in tumor cell cytoplasm (original magnification, 200 \times\). It is evident that the abundance of VEGF-positive tumor cells is higher in the lipiodol TAE group (G) and NS control group (H) than in the ATON plus hyperthermia group (E) or ATON embolization alone group (F).

doi:10.1371/journal.pone.0017926.g008
Materials and Methods

Animal Models and Groups

All animal procedures were performed in accordance with the approval and guidelines of the Institutional Animal Care and Use Committee (IACUC) of the Medical School of Southeast University (approval ID: SYXK-2007.2121). Sixty male New Zealand white rabbits (provided by Southeast University, Nanjing, China) were randomly assigned to five groups \( n = 12 \) each; Fig. 10). An orthotopic model of hepatocarcinoma was developed using VX2 carcinoma as described previously [42]. The animals from each group received a hepatic arterial infusion of arsenic trioxide (As2O3) nanoparticles (ATONs) (Groups 1, 2, and 5), lipiodol (Group 3), or saline (Group 4). In Groups 1 and 5, hyperthermia was induced on day 3 after transcatheter arterial embolization (TAE). Four rabbits from Groups 1 to 4 were sacrificed on day 7 for histopathological examination after TAE, whereas the remaining eight animals in each group were kept for the survival study. Animals in Group 5 were used for dynamic measurement of temperatures during the hyperthermia procedure, and were serially sacrificed at 1, 3, 10, and 14 days after TAE (three rabbits each day) to verify the distribution of ATONs.

Treatment Procedure, Temperature, and Tumor Response Measurement

TAE was performed (H.Y., G.Y.Z.) at 14 days after tumor implantation using an angiography system (Innova 3100, GE Medical Systems, Milwaukee, WI, USA) according to a method described previously [43]. Briefly, using an aseptic technique, the

Table 3. Plasma VEGF Levels in Different Groups.

| Group | Plasma VEGF Level (pg/ml) | Day 0  | Day 3  | Day 7  | Day 10 | Day 14 | Day 21 |
|-------|---------------------------|-------|-------|-------|-------|-------|-------|
| 1     | 64.95 ± 19.98             | 95.00 ± 40.10 \( ^b \) | 58.37 ± 21.19 \( ^c \) | 49.40 ± 20.03 \( ^c \) | 38.33 ± 17.88 \( ^c \) | 29.21 ± 8.18 \( ^c \) |
| (n = 8) | (n = 7)     | (n = 7) | (n = 7) | (n = 7) | (n = 7) | (n = 7) | (n = 7) |
| 2     | 67.01 ± 19.29             | 98.08 ± 31.47  \( ^d \) | 70.13 ± 30.39  \( ^d \) | 54.89 ± 20.52  \( ^e \) | 45.69 ± 15.96  \( ^e \) | 44.56 ± 13.79  \( ^e \) |
| (n = 8) | (n = 8)     | (n = 8) | (n = 8) | (n = 8) | (n = 8) | (n = 8) | (n = 8) |
| 3     | 62.54 ± 20.26             | 159.67 ± 48.23  \( ^f \) | 174.57 ± 27.57  \( ^f \) | 166.67 ± 38.12  \( ^f \) | 95.48 ± 31.97  \( ^f \) | 83.94 ± 17.99  \( ^f \) |
| (n = 8) | (n = 7)     | (n = 7) | (n = 7) | (n = 6) | (n = 6) | (n = 6) | (n = 5) |
| 4     | 63.10 ± 20.51             | 82.21 ± 20.51  | 87.33 ± 27.75  | 98.12 ± 18.44  | 172.97 ± 30.60 | 298.00 ± 79.37 |
| (n = 8) | (n = 8)     | (n = 8) | (n = 8) | (n = 8) | (n = 6) | (n = 3) |

Mann-Whitney U Test:
\( ^a \) G1 vs. G2 \( p = 0.021 \);
\( ^b \) G1 vs. G3 \( p < 0.05 \);
\( ^c \) G1 vs. G4 \( p < 0.05 \);
\( ^d \) G2 vs. G3 \( p < 0.05 \);
\( ^e \) G2 vs. G4 \( p < 0.05 \);
\( ^f \) G3 vs. G4 \( p < 0.05 \).

doi:10.1371/journal.pone.0017926.t003

Table 4. Comparisons of Tissue VEGF levels at Day 7 between groups.

| Group | Tissue VEGF at Day 7 (mean ± SD) pg/mg protein | VEGF expression at day 7 (10 sections/Tumor) | Positive Rate(%) |
|-------|---------------------------------------------|-----------------------------------------------|------------------|
|       |                                              | −                | ±                | +                |                   |
| 1 (n = 4) | 30.05 ± 7.12 \( ^a,b,c \) | 32            | 5                | 3                | 8/40 (20%) \( ^h,i \) |
| 2 (n = 4) | 41.22 ± 9.25 \( ^d,e \) | 28            | 5                | 7                | 12/40 (30%) \( ^j,k \) |
| 3 (n = 4) | 97.64 ± 17.31 \( ^f \) | 28            | 5                | 7                | 34/40 (85%) \( ^l \) |
| 4 (n = 4) | 60.85 ± 11.16 \( ^g \) | 18            | 16               | 6                | 22/40 (55%)       |

Abbreviations: − (negative); ± (weakly positive); + (positive).

Mann-Whitney U Test:
\( ^a \) G1 vs. G2 \( p = 0.003 \);
\( ^b \) G1 vs. G3 \( p = 0.000 \);
\( ^c \) G1 vs. G4 \( p = 0.000 \);
\( ^d \) G2 vs. G3 \( p = 0.000 \);
\( ^e \) G2 vs. G4 \( p = 0.000 \);
\( ^f \) G3 vs. G4 \( p = 0.000 \).

Chi-square test:
\( ^g \) G1 vs. G2 \( p = 0.000 \);
\( ^h \) G1 vs. G3 \( p = 0.000 \);
\( ^i \) G1 vs. G4 \( p = 0.000 \);
\( ^j \) G2 vs. G3 \( p = 0.000 \);
\( ^k \) G2 vs. G4 \( p = 0.000 \);
\( ^l \) G3 vs. G4 \( p = 0.000 \).

doi:10.1371/journal.pone.0017926.t004
right femoral artery of an anesthetized rabbit (1% sodium pentobarbital at 4 mL/kg intravenous infusion, Shanghai Chemical Reagent Co., Shanghai, China) was accessed via surgical cutdown and a 4F vascular sheath was placed (Terumo, Tokyo, Japan). Selective catheterization of the proper hepatic artery feeding the VX2 carcinoma was performed using a 3F microcatheter (SP, Terumo, Tokyo, Japan), which was coaxially inserted through a 4F Cobra catheter (Cook Inc., Bloomington, IN, USA) with fluoroscopic guidance. Hepatic angiography was obtained with hand injection of 3 mL of contrast medium (Omnipaque 300; Figure 9. Kaplan-Meier survival analysis of liver-tumor-bearing rabbits. Graph of the Kaplan-Meier method with the log-rank test shows a significant survival benefit for the animals treated with ATON embolization alone or plus hyperthermia compared with those in Groups 3 and 4. doi:10.1371/journal.pone.0017926.g009

![Survival Functions](image)

**Figure 10. Flow chart of the experiment.** Flow chart of the experiment and diagram showing experimental groups according to the embolization agents that were used for intra-arterial delivery. doi:10.1371/journal.pone.0017926.g010
Ansheng Pharmaceutical Co., Shanghai, China) that was injected at a rate of approximately 0.5 mL/s.

\( \text{As}_2\text{O}_3 \) nanoparticles (ATONs; approximately 40 nm in diameter; 83.30% (wt/wt) \( \gamma \)-Fe$_2$O$_3$ HeCo coated with 11.50% (wt/wt) \( \text{As}_2\text{O}_3 \)) were made in our laboratory according to a method described previously [31,44]. A thin layer of ATONs was spread and exposed to ultraviolet light for sterilization. The ATONs were then magnetically separated and quantitatively dissolved in lipiodol (Laboratoire Guerbat, France; 80 mg ATONs/1 mL lipiodol) via ultrasonography.

After the desired ATON suspension dose (24 mg ATONs, including net \( \gamma \)-Fe$_2$O$_3$ 21.2 mg plus net \( \text{As}_2\text{O}_3 \) 2.8 mg per kg body weight) had been carefully infused through the 3F microcatheter into the tumor-feeding artery, the femoral artery was ligated and the wound was closed. Selective catheterization of the tumor-feeding artery under a DSA monitor guaranteed tumor target embolization and spared arterial flow through the hepatic artery into the liver.

Three days after TAE, using the general anesthesia protocol and aseptic technique described above, a puncture needle (18G, Terumo, Tokyo, Japan) was percutaneously advanced into the center or the rim of the tumor, the normal liver 1 cm from the tumor rim, and the rectum, under CT guidance (Fig. 11). The needle stylet was then replaced with a fiberoptic temperature probe (FISO Inc., Quebec, QC, CA). This CT-guided percutaneous puncture and temperature measurement technique minimized potential heat loss to the external environment. Animals were subjected to the AEH therapy system (Figs. 12A, B) described previously (frequency, 80 kHz; field strength, 5–10 kA/m) [28,29]. Each probe tip temperature, wattage, field intensity, and frequency was recorded during the procedure. After the tumor core temperature had reached the intended temperature (42.5°C), it was maintained at 42–45°C for a period of 30 min by manually adjusting the magnetic field strength. The temperature of the liver itself was maintained at approximately 37.0°C.

Plain CT scanning was performed to evaluate the ATON distribution and each tumor’s longest dimension (GE HiSpeed CT1 Scanner, GE Medical Systems, Milwaukee, WI, USA) at days 0, 3, 4, 7, 10, 14, and 21 with parameters of 120 kV, 200 mA, FOV 16 cm, slice thickness 3 mm, pitch 1.5 mm, reconstruction 2 mm, and matrix 512.

Response Evaluation Criteria in Solid Tumors (RECIST) criteria were used to determine objective responses to treatment [18,43,46]. A complete response (CR) was defined as the disappearance of all lesions with no new lesion development; a partial response (PR) as a decrease of 30% or more in the longest dimension (LD) or the sum of the longest dimensions of all measured target lesions; stable disease (SD) as any change in tumor size that did not satisfy PR or PD criteria; and progressive disease (PD) as an increase of >20% in the longest dimension or the sum of the longest dimensions of all measured target lesions or any new lesion. All CT images were blindly analyzed by two radiologists (Q.L. and H.Z.N., who had 15 and 12 years of experience, respectively) by consensus.

Biochemical Studies and Vascular Endothelial Growth Factor Assay

Peripheral blood samples (2.0 mL) were collected for biochemical examination at days 0, 3, 4, 7, 10, 14, and 21 after treatment. Plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), Hserum creatinineH (Cr), and total bilirubin (Tbil) levels were measured using a biochemical autoanalyzer (Model LX 20; Beckman, CA, USA).

The tumor tissues were prepared as described previously [47]. Vascular endothelial growth factor (VEGF) levels of plasma and tumor tissue were measured using an ELISA assay (RapidBio, CA, USA) according to the manufacturer’s instructions. Each sample was measured in triplicate.

Histopathological and Immunohistochemical Examinations

The animals were sacrificed by intravenous injection of an overdose of sodium pentobarbital at the defined endpoint. The intact liver, lungs, kidneys, spleen, and any metastases were removed and fixed in 10% buffered formalin, and were then carefully sectioned in 4-μm-thickness in the axial plane to correspond with the plane of the CT scan. All paraffin-embedded, hematoxylin and eosin (H&E)-stained sections were examined microscopically.

To assess VEGF expression, 10 random non-necrotic areas (×200) from each specimen were evaluated [48] using a VEGF monoclonal antibody (Santa Cruz Biotechnology Inc., CA, USA). Experiments were performed according to the supplier’s instructions. VEGF expression was semiquantitatively evaluated at three levels: positive staining in less than 10% was regarded as negative (−), positive staining in 10–50% as weakly positive (+), and positive staining in 50% or more as positive (+) [49]. For determination of MVD, paraffin-embedded sections were stained with an anti-CD31 rabbit monoclonal antibody (DAKO Corp., Carpinteria, CA, USA) following a standard SABC procedure, according to a method described previously [50]. Briefly, five fields of “vascular hot spots” with a 200-fold magnification in each tumor section obtained at 7 days after TAE were examined, and the mean MVD value was recorded in a blinded fashion. The percentage of the necrotic area in the entire tumor area was calculated from H&E sections according to a method described previously [30].
Figure 12. Arterial embolization hyperthermia therapy system. Figure 12A Scheme of AEH therapy system and method of temperature measurement in vivo. Four FISO probe fibers that were attached to the inside wall of a plastic tube connected to a computer were used to detect temperature changes in the tumor core, tumor rim, and 1 cm from the tumor and rectum. Figure 12B Apparatus of new arterial embolization hyperthermia therapy system for large animals or humans. The system comprises a generator (G), induction coil (C), treatment table (T), and FISO probe (P).

Histopathological slides were examined with a Scope.A1 microscope (ZEISS, Germany) equipped with an Axiocam MR3 digital camera and Image-Pro Plus version 6.0 (Media Cybernetics, Silver Spring, MD). An experienced pathologist (Z.Y.W) who was blinded to the experiment details evaluated all specimens.

Statistical analyses
Statistical evaluation was performed using SPSS software (ver. 13.0); SPSS Inc., Chicago, IL, USA). Numerical data were expressed as means±SD. A P value<0.05 was considered to indicate statistical significance. The Kruskal-Wallis and Mann-Whitney U tests were performed among groups. Survival rates were assessed using the Kaplan-Meier method.

Supporting Information
Figure S1 The magnetic properties of γ-Fe₂O₃ nanoparticles and ATONs. The magnetic properties of γ-Fe₂O₃ nanoparticles and ATONs were shown in a hysteresis loop according to a method described previously [28,29], indicating a higher specific absorption rate of γ-Fe₂O₃ nanoparticles than that of ATONs under an alternating current magnetic field of 10 kA/m and 80 kHz. (TIF)

Acknowledgments
We thank Prof. Yi Miao (Department of general surgery, People’s Hospital of Jiangsu Province, China) for providing VX2 carcinoma tissues. We thank Prof. Sanjiv Sharma (All India Institute of Medical Sciences, New Delhi, India) and Dr. Feiyu Xue for their critical review and discussion.

Author Contributions
Conceived and designed the experiments: HY G-JT H-ZN R-ZX NG D-SZ. Performed the experiments: HY R-ZX G-YZ QL GD G-ZL. Analyzed the data: HY H-ZN R-ZX QL G-YZ. Contributed reagents/materials/analysis tools: NG D-SZ Z-YW HY. Wrote the manuscript: HY G-JT.

References
1. He J, Gu D, Wu X, Reynolds K, Duan X, et al. (2005) Major causes of death among men and women in China. N Engl J Med 353: 1124–1134.
2. Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. (2002) Arterial embolization hyperthermia in a rabbit liver tumour model. Int J Hyperthermia 18: 117–128.
3. Pacella CM, Bizzarri G, Cecconi P, CaspaniB, Magnolfi F, et al. (2001) Hepatocellular carcinoma: Long-term results of combined treatment with laser thermal ablation and transcatheter chemoembolization. Radiology 219: 669–678.
4. Vogl T, Mack MG, Balzer JO, Eszhelmann K, Straub R, et al. (2003) Liver metastases: Noduvadit downsizing with transarterial chemoembolization before laser-induced phototherapy. Radiology 229: 457–464.
5. Llovet JM, De Bisciglia AM, Bruij J, Kramer BS, Lencioni R, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 690–711.
6. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians 55: 74–108.
7. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians 55: 74–108.
8. Moroz P, Jones SK, Winter J, Gray BN (2001) Targeting liver tumors with Arterial Embolization Hyperthermia on Hepatoma according to a method described previously [28,29], indicating a higher specific absorption rate of γ-Fe₂O₃ nanoparticles than that of ATONs under an alternating current magnetic field of 10 kA/m and 80 kHz. (TIF)

PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e17926

Author Contributions
Conceived and designed the experiments: HY G-JT H-ZN R-ZX NG D-SZ. Performed the experiments: HY R-ZX G-YZ QL GD G-ZL. Analyzed the data: HY H-ZN R-ZX QL G-YZ. Contributed reagents/materials/analysis tools: NG D-SZ Z-YW HY. Wrote the manuscript: HY G-JT.
of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216.

19. Llovet JM, Brux J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429–442.

20. Marabili L, Stigliano R, Triantos C, Senzolo M, Chelougtias E, et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6–25.

21. Biodato M, Marrone G, Racco S, Di Stasi C, Miele L, et al. (2010) Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 14: 356–362.

22. Johannsen M, Gnevvekou U, Eckeli L, Feusner A, Waldoffer N, et al. (2005) Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 21: 637–647.

23. Vogl TJ, Strauss R, Eckeli K, Sollner O, Mack MG (2004) Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy–local tumor control rate and survival data. Radiology 230: 450–458.

24. Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, et al. (2000) Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2: 555–560.

25. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, et al. (2003) Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 19: 575–589.

26. Zhu AL, Liu LX, Piao DX, Lin YX, Zhao JP, et al. (2004) Liver regional continuous chemotherapy: use of femoral or subclavian artery for percutaneous implantation of catheter-port systems. World J Gastroenterol 10: 1659–1662.

27. Morez P, Pardoe H, Jones SK, St Pierre TG, Song S, et al. (2002) Arterial embolization hyperthermia: hepatic iron particle distribution and its potential determination by magnetic resonance imaging. Phys Med Biol 47: 1591–1602.

28. Ruizhi X, Hui Y, Yu Z, Ming M, Zhongping C, et al. (2009) Three-Dimensional Model for Determining Inhomogeneous Thermal Dosage in a Liver Tumor During Arterial Embolization Hyperthermia Incorporating Magnetic Nanoparticles. Magnetics, IEEE Transactions on 45: 3085–3091.

29. Ruizhi X, Yu Z, Ming M, Jingzhang X, Jiewei L, et al. (2007) Measurement of Specific Absorption Rate and Thermal Simulation for Arterial Embolization Hyperthermia in the Maghemite-Gelled Model. Magnetics, IEEE Transactions on 43: 1078–1085.

30. Hamaguchi S, Toinai I, Ito A, Mimasu K, Shigetomi T, et al. (2003) Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94: 834–839.

31. Wang ZY, Song J, Zhang DS (2009) Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol 15: 2995–3002.

32. Park MJ, Park IC, Soo KM, Lee SH, et al. (2003) Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol 22: 1271–1276.

33. Patterson J, Strang R (1979) The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 5: 235–241.

34. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59: 6033–6037.

35. Lew YS, Kolouškova Y, Brown SL, Kim JH (2002) Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 62: 4202–4203.

36. Kinjo K, Kizaki M, Muto A, Fukushima Y, Umezawa A, et al. (2000) Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in bFGF-CSF-producing transgenic SCID mice. Leukemia 14: 431–438.

37. Monzen H, Griffin RJ, Williams BW, Amano M, Ando S, et al. (2004) Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. Radiat Med 22: 205–211.

38. Hines-Peralta A, Sukhatme V, Regan M, Signorotti S, Liu JZ, et al. (2006) Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 240: 82–89.

39. Kito M, Matsumoto K, Wada N, Sera K, Futagawa S, et al. (2003) Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 94: 1010–1014.

40. Xu HY, Yang YL, Liu SM, Bi L, Chen SX (2004) Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World J Gastroenterol 10: 3677–3679.

41. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, et al. (2007) Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 25: 77–84.

42. Lu Q, Teng GJ, Zhang Y, Niu HZ, Zhu GY, et al. (2008) Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through transarterial delivery. Cancer Biol Ther 7: 219–224.

43. Yoon CJ, Chang JW, Park JH, Yoon YH, Lee JW, et al. (2003) Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229: 126–131.

44. Yan S, Zhang D, Gu N, Zheng J, Ding A, et al. (2005) Therapeutic effect of Fe2O3 nanoparticles combined with magnetic fluid hyperthermia on cultured liver cancer cells and xenograft liver cancers. J Nanosci Nanotechnol 5: 1185–1192.

45. Hajitou A, Levy DC, Hannay JA, Korchin B, Staquicini FI, et al. (2008) A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A 105: 4471–4476.

46. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e9472.

47. Yoshiji H, Kuriyama S, Yoshi J, Ikenaka Y, Noguchi R, et al. (2002) Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834–842.

48. Hassounouch B, Islam M, Nagel T, Pan Q, Merajver SD, et al. (2007) Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 6: 1039–1045.

49. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, et al. (1998) Antitumor effect of arsenic trioxide (As2O3) on human cancer cells and xenograft liver cancers. J Nanosci Nanotechnol 5: 1185–1192.

50. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A 105: 4471–4476.

51. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e9472.